Literature DB >> 10404768

Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables.

G D Lowe1, A Rumley, M Woodward, E Reid, J Rumley.   

Abstract

Activated protein C (APC) resistance, defined as a low APC ratio, is associated with the factor V mutation R506Q (factor V Leiden). APC ratio may also be influenced by other clinical and coagulation variables, which we studied in 460 men and 495 women aged 25-74 years, from a random population sample (Glasgow MONICA Survey). APC ratio correlated positively with APTT; and inversely with factor VIIIc, factor IXc, antithrombin activity, prothrombin F1+2 fragment, and thrombin-antithrombin complexes; but not with other coagulation variables. APC ratio decreased with age, but APTT did not. APC ratio and APTT were significantly lower in women versus men, and were significantly lower in users of oral contraceptives or hormone replacement therapy. The FV:R506Q mutation (prevalence 2.5%) was associated with lower APC ratio and protein C and S activities and with higher factor VIIIc levels; but not with increases in F1+2 fragment or thrombin-antithrombin complexes. APC ratio correlated inversely with total cholesterol and diastolic blood pressure; and in women with triglycerides, systolic blood pressure, and body mass index. Obesity was associated with a significantly lower APC ratio. In contrast, smoking markers correlated positively with APC ratio in men. These associations of APC ratio may be relevant to the increased risks of venous thrombosis with age, female sex, oestrogen use, obesity and high factor VIIIc levels. The association of APC resistance with elevated plasma levels of coagulation markers suggests that this phenotype represents an in vivo hypercoagulable state.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404768

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  11 in total

1.  Common variants of large effect in F12, KNG1, and HRG are associated with activated partial thromboplastin time.

Authors:  Lorna M Houlihan; Gail Davies; Albert Tenesa; Sarah E Harris; Michelle Luciano; Alan J Gow; Kevin A McGhee; David C Liewald; David J Porteous; John M Starr; Gordon D Lowe; Peter M Visscher; Ian J Deary
Journal:  Am J Hum Genet       Date:  2010-03-18       Impact factor: 11.025

Review 2.  Thrombophilia in pregnancy.

Authors:  I D Walker
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

3.  Associations of Hemostatic Variables with Cardiovascular Disease and Total Mortality: The Glasgow MONICA Study.

Authors:  Gordon D O Lowe; Sanne A E Peters; Ann Rumley; Hugh Tunstall-Pedoe; Mark Woodward
Journal:  TH Open       Date:  2022-05-26

Review 4.  Drug-induced thrombosis: an update.

Authors:  Yuval Ramot; Abraham Nyska; Galia Spectre
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

5.  Meta-analysis of Factor V Leiden G1691A polymorphism and osteonecrosis of femoral head susceptibility.

Authors:  Xifu Shang; Zhengliang Luo; Xu Li; Fei Hu; Qichun Zhao; Wenzhi Zhang
Journal:  Biomed Rep       Date:  2013-04-09

Review 6.  Coagulation and fibrinolysis abnormalities in obesity.

Authors:  G De Pergola; N Pannacciulli
Journal:  J Endocrinol Invest       Date:  2002-11       Impact factor: 4.256

7.  Associations between blood coagulation markers, NT-proBNP and risk of incident heart failure in older men: The British Regional Heart Study.

Authors:  S Goya Wannamethee; Peter H Whincup; Olia Papacosta; Lucy Lennon; Gordon D Lowe
Journal:  Int J Cardiol       Date:  2016-12-20       Impact factor: 4.164

8.  Metabolites Associated With the Risk of Incident Venous Thromboembolism: A Metabolomic Analysis.

Authors:  Xia Jiang; Oana A Zeleznik; Sara Lindström; Jessica Lasky-Su; Kaitlin Hagan; Clary B Clish; A Heather Eliassen; Peter Kraft; Christopher Kabrhel
Journal:  J Am Heart Assoc       Date:  2018-11-20       Impact factor: 5.501

9.  A gene-centric analysis of activated partial thromboplastin time and activated protein C resistance using the HumanCVD focused genotyping array.

Authors:  Tom R Gaunt; Gordon D O Lowe; Debbie A Lawlor; Juan-Pablo Casas; Ian N M Day
Journal:  Eur J Hum Genet       Date:  2012-11-28       Impact factor: 4.246

Review 10.  Iron Metabolism in Obesity and Metabolic Syndrome.

Authors:  Álvaro González-Domínguez; Francisco M Visiedo-García; Jesús Domínguez-Riscart; Raúl González-Domínguez; Rosa M Mateos; Alfonso María Lechuga-Sancho
Journal:  Int J Mol Sci       Date:  2020-08-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.